Divi's Laboratories Reports Strong Q1FY27 Earnings Amid Premium Valuation
· Business · LiveMint, Investing.com
Divi's Laboratories, a leading Indian pharmaceutical manufacturer, reported a consolidated total income of ₹31.44 billion in Q1FY27, up from ₹25.29 billion year-on-year. Profit after tax increased to ₹9.02 billion from ₹5.45 billion in the same period. The company maintains a debt-free balance sheet, but its shares trade at a high price-to-earnings (PE) multiple of 86 and a price-to-book (PB) ratio of 13.6, significantly above the BSE Healthcare index averages. Management noted a challenging external operating environment, particularly concerning global trade routes and sourcing channels linked to West Asia.
Why it matters
Divi's Laboratories' strong earnings growth demonstrates its operational resilience despite global challenges, but its premium valuation suggests high market expectations. Investors must weigh the company's growth prospects against its expensive share price.
Read the original report — LiveMint
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.